Carney complex (CNC). by Bertherat, Jérôme
Carney complex (CNC).
Je´roˆme Bertherat
To cite this version:
Je´roˆme Bertherat. Carney complex (CNC).. Orphanet Journal of Rare Diseases, BioMed
Central, 2006, 1, pp.21. <10.1186/1750-1172-1-21>. <inserm-00089834>
HAL Id: inserm-00089834
http://www.hal.inserm.fr/inserm-00089834
Submitted on 24 Aug 2006
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
BioMed Central
Page 1 of 6
(page number not for citation purposes)




Address: Centre de Référence Maladies Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin, INSERM U 567, CNRS UMR 8104, Institut 
Cochin, Université René-Descartes Paris 5, Paris, 75014, France
Email: Jérôme Bertherat* - jerome.bertherat@cch.ap-hop-paris.fr
* Corresponding author    
Abstract
The Carney complex (CNC) is a dominantly inherited syndrome characterized by spotty skin
pigmentation, endocrine overactivity and myxomas. Skin pigmentation anomalies include lentigines
and blue naevi. The most common endocrine gland manifestations are acromegaly, thyroid and
testicular tumors, and adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome
due to primary pigmented nodular adrenocortical disease (PPNAD). PPNAD, a rare cause of
Cushing's syndrome, is due to primary bilateral adrenal defect that can be also observed in some
patients without other CNC manifestations or familial history of the disease. Myxomas can be
observed in the heart, skin and breast. Cardiac myxomas can develop in any cardiac chamber and
may be multiple. One of the putative CNC genes located on 17q22-24, (PRKAR1A), has been
identified to encode the regulatory subunit (R1A) of protein kinase A. Heterozygous inactivating
mutations of PRKAR1A were reported initially in 45 to 65 % of CNC index cases, and may be
present in about 80 % of the CNC families presenting mainly with Cushing's syndrome. PRKAR1A
is a key component of the cAMP signaling pathway that has been implicated in endocrine
tumorigenesis and could, at least partly, function as a tumor suppressor gene. Genetic analysis
should be proposed to all CNC index cases. Patients with CNC or with a genetic predisposition
to CNC should have regular screening for manifestations of the disease. Clinical work-up for all
the manifestations of CNC should be performed at least once a year in all patients and should start
in infancy. Cardiac myxomas require surgical removal. Treatment of the other manifestations of
CNC should be discussed and may include follow-up, surgery, or medical treatment depending on
the location of the tumor, its size, the existence of clinical signs of tumor mass or hormonal excess,
and the suspicion of malignancy. Bilateral adrenalectomy is the most common treatment for
Cushing's syndrome due to PPNAD.
Disease name/synonyms
Carney complex.
The complex of cardiac myxomas, endocrine overactivity
and spotty pigmentation.
Definition/diagnostic criteria
The Carney complex (CNC) was first described in 1985 by
J. Aidan Carney, as the combination of myxomas, spotty
pigmentation and endocrine overactivity [1]. It is defined
by the association of multiple endocrine neoplasia and
cardiocutaneous manifestations. Patients previously char-
acterized as LAMB (lentigineses, atrial myxoma, mucocu-
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taneous myxoma, blue nevi) or NAME (nevi, atrial
myxoma, myxoid neurofibroma, ephelide) could be con-
sidered as having Carney complex. Numerous organs may
be involved in CNC and the manifestations vary greatly
among patients. Some of them are quite specific, such as
primary pigmented nodular disease (PPNAD), while oth-
ers show little specificity, such as thyroid nodes or blue
nevi. It is generally assumed that a patient presenting with
two or more of the manifestations listed in Table 1 would
be diagnosed as having Carney complex. This table lists
the most frequent features of CNC and their estimated fre-
quency [according to references [1,3-5,8] and our per-
sonal observations]. The incidence of each manifestation
depends on its presentation and might not reflect true
prevalence. For instance, according to autopsy studies
PPNAD is a constant feature in CNC patients [8], how-
ever, reports of Cushing syndrome in the literature indi-
cate that only 25 to 45 % of CNC patients have PPNAD. It
has been established that at least two of these manifesta-
tions need to be present to confirm the diagnosis of CNC.
If the patient has a germline PRKAR1A mutation and/or a
first-degree relative affected by CNC, a single manifesta-
tion is sufficient for the diagnosis.
Epidemiology
CNC is a rare disease. About 500 patients have been regis-
tered by the NIH-Mayo Clinic (USA) and the Cochin
center (France) [2]. Cumulative reports from these cent-
ers, plus information from the Cornell center in New
York, indicate that there are about 160 index cases of CNC
presently known [3-6].
Clinical description
The manifestations of CNC can be numerous and vary
between patients. Even in the same kindred, phenotypic
variability can be observed. The estimated frequencies of
these manifestations are listed in Table 1. Endocrine, der-
matologic and cardiac anomalies are the main manifesta-
tions of the disease.
Skin lesions
The lentiginosis is observed in most patients and is so
characteristic that can makes the diagnosis. It appears as
small (2 to 10 mm) brown to black macules typically
located around the upper and lower lips, on the eyelids,
ears and the genital area. Multiple blue nevi and junc-
tional or compound nevi may also be observed in CNC,
as well as cutaneous myxomas. The skin myxomas present
as non-pigmented subcutaneous nodules. Myxomas can
also be located in the ear canal.
Endocrine tumors
The following types of endocrine gland tumors are
observed in CNC patients: growth hormone (GH)-secret-
ing pituitary adenomas (acromegaly), thyroid adenomas
or carcinomas, testicular tumors (large-cell calcifying Ser-
toli cell tumors), and ovarian cysts. Adrenocorticotropic
hormone (ACTH)-independent Cushing's syndrome due
to PPNAD is observed in 25 to 30 % of patients with CNC.
PPNAD is a rare disease observed mostly in patients with
CNC. The disease was named after the macroscopic
appearance of the adrenals that is characterized by the
small pigmented micronodules observed in the cortex
(Figure 1) [7]. The disease is usually bilateral with primary
involvement of both adrenals. Cushing's syndrome due to
PPNAD is observed in children and young adults, with a
peak during the second decade of life [8]. It is rare, but can
occur before the age of 4-yr and it is rarely diagnosed after
the age of 40-yr. Diagnosis of Cushing's syndrome due to
PPNAD is often difficult because hypercortisolism can
develop progressively over years. In contrast, a large and
rapid burst of cortisol excess can be observed in some
patients, which might spontaneously regress. In some
cases of PPNAD, clearly cyclic forms of hypercortisolism
have been documented [6,9,10]. PPNAD can also be diag-
nosed by systematic screening in patients with CNC inves-
tigated for other clinical manifestations of the complex or
after familial screening. Despite the unusual time course
of Cushing's syndrome observed in some patients with
Table 1: Main features and diagnostic criteria of Carney complex. 
This table lists the most frequent features of CNC and their 
estimated frequency [according to references 1, 3–5, 8 and our 
personal observations]. The incidence of each manifestation 
depends on its presentation and might not reflect true 
prevalence. For instance, according to autopsy studies PPNAD is 
a constant feature in CNC patients [8], however, reports of 
Cushing syndrome in the literature indicate that only 25 to 45 % 
of CNC patients have PPNAD and our personnal experience 
suggests that about 60 % of CNC patients systematically 
investigated have PPNAD. It has been established that at least 
two of these manifestations (except ovrian cyst) need to be 
present to confirm the diagnosis of CNC. If the patient has a 
germline PRKAR1A mutation and/or a first-degree relative 
affected by CNC, a single manifestation is sufficient for the 
diagnosis.
Main features of Carney complex (%)







Breast ductal adenoma 25
Testicular tumors (LCCSCT: Large-Cell Calcifying Sertoli 
Cell Tumor) (in male)
33–56
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PPNAD, clinical signs are quite similar to those observed
in patients presenting with other causes of hypercortiso-
lism. Urinary cortisol is increased in most patients at the
time of diagnosis of PPNAD, but its level can be highly
variable. The circadian rhythm of cortisol secretion is usu-
ally completely abolished. As with ACTH-independent
Cushing's syndrome due to other causes, patients with
PPNAD have low plasma levels of ACTH and show no
stimulation of cortisol or ACTH secretion after corticotro-
pin-releasing hormone (CRH) injection. In addition, dex-
amethasone fails to suppress cortisol secretion, even after
high dose administration. Pathological investigation
reveals that adrenal glands from patients with PPNAD are
usually normal in size and weight (between 4 to 17 g) [8].
In keeping with this finding, adrenals appear normal on
computed tomography (CT)-scan in one out of three
patients (Figure 1). In the other patients, micronodules
can be visible and, more rarely, macronodules (>1 cm
diameter) in one or both glands. Iodocholestrol scintigra-
phy, when performed, usually shows a bilateral uptake
despite ACTH suppression by endogenous hypercortiso-
lism.
Acromegaly due to a pituitary GH-secreting tumor is not
very frequent, but most patients with CNC present with a
mild increase in GH, and sometimes in prolactin (PRL)
secretion. Alterations in the rhythm of GH secretion are
frequently observed.
Thyroid tumors are most often benign, non-toxic adeno-
mas, mostly of follicular type. Some patients present with
papillary carcinoma that can be multiple and sometimes
quite aggressive.
Testicular tumors are easily detected by ultrasound inves-
tigation as bilateral microcalcifications. Ovarian cysts and
cystadenoma have been observed in CNC patients.
Cardiac myxomas
Cardiac myxoma is an important manifestation of CNC.
It may be the cause of the high rate (16 %) of sudden
death historically reported in CNC families [11], thus
underlying the importance of its early diagnosis. In the
past, underdiagnosis of cardiac myxomas may have
accounted for the majority of deaths due to CNC. In con-
trast with sporadic myxoma, they can develop in any car-
diac chamber and may be multiple. Cardiac myxoma can
be the cause of stroke due to embolism and cardiac defi-
ciency. It is therefore important to screen regularly (by
ultrasound) patients with CNC for the presence of cardiac
myxoma. In difficult cases, trans-esophageal ultrasound
and cardiac magnetic resonance imaging (MRI) can be
very helpful.
Other tumors
Various other tumors, some of them quite specific for
CNC, can be observed. Melanotic schwannoma is a rare
tumor and occurs mainly in CNC. It is a pigmented tumor
Macroscopic and CT-scan findings in primary pigmented nodular adrenocortical disease (PPNAD)Figure 1
Macroscopic and CT-scan findings in primary pigmented nodular adrenocortical disease (PPNAD) A: Macroscopic appearance 
of the adrenal gland in PPNAD. The cut surfaces show multiple pigmented micronodules. The periadrenal fat is also visible 
around the adrenal capsule. B: Adrenal CT-scan in PPNAD. A micronodule is visible on the external part of the left adrenal on 
the CT-scan shown (see red arrow).
A B
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that can be misdiagnosed as a melanoma. This tumor can
be observed in any periphal nerve and can be, in rare
cases, malignant. Breast ductal adenomas, breast myxo-
mas, and osteochondromyxoma are among the tumors
also observed in CNC.
Etiology/genetics of CNC
The first description of CNC included 40 patients [1],
among them 10 were familial cases, leading to the
hypothesis of a genetic origin, at least in a subset of
patients. CNC seems to be a genetically heterogeneous
disease and linkage analysis has shown that at least two
loci are involved: 2p16 and 17q22-24 [11,12]. The CNC1
gene, located on 17q22-24, has been identified as the reg-
ulatory subunit (R1A) of the protein kinase A (PRKAR1A)
[13,14]. PRKAR1A is a key component of the cAMP sign-
aling pathway that has been implicated in endocrine tum-
origenesis. Heterozygous inactivating mutations of
PRKAR1A have been detected in about 45 to 65 % of CNC
families [3,4]. In CNC patients with Cushing's syndrome
the frequency of PRKAR1A mutations is about 80 %, sug-
gesting that families with PPNAD are more likely to carry
a 17q22-24 defect [5]. Interestingly, patients with isolated
PPNAD and no familial history of CNC may also carry a
germline de novo mutation in PRKAR1A [6]. In the tumors
of CNC patients loss of heterozygosity (LOH) at 17q22-
24 may be observed, suggesting that PRKAR1A is a tumor
suppressor gene. Somatic mutation of PRKAR1A in a
patient with PPNAD already carrying a germline mutation
may lead to inactivation of the wild type allele [6]. How-
ever, inactivation of the remaining wild type allele by
genetic alteration does not appear to be a constant step in
PPNAD and CNC tumor development [5]. In a mice trans-
genic model with heterozygous inactivation of PRKAR1A,
tumors may develop without allelic loss [4]. This suggests
that the classic model of tumor suppressor gene with a
germline inactivating first allelic alteration, followed by a
second genetic hit leading to inactivation of the remaining
wild type allele, might to some extent be applicable to
PRKAR1A. It is also possible that in PPNAD, a general pol-
yclonal expansion might be stimulated by haploinsuffi-
ciency due to the first germline defect; a second genetic hit
would then lead to inactivation of the wild type allele and
further stimulate tumorigenesis and the development of
adrenocortical nodules.
A putative CNC2 gene located at the 2p16 locus remains
to be determined [3,11]. Somatic alterations of the 2p16
region have been reported in CNC tumors, even in
patients with mutation of the CNC1 gene (i.e. PRKAR1A
located on 17q22-24) [15]. These alterations are usually
gene amplifications, suggesting that the gene located at
2p16 is a potential oncogene. Considering the genetics in
isolated PPNAD, it should be mentioned that the clinical
manifestations in a subgroup of very young PPNAD
patients may differ from those in older patients with CNC.
In these patients the classical pathological finding of pig-
mented nodules may be absent although micronodules
are present [10,16]. In this subgroup of very young
PPNAD patients, Cushing's syndrome may occur between
birth and the age of 5-yrs. The main reason for differenti-
ating this group of PPNAD or PPNAD-like patients is the
lower rate of germline inactivating mutation.
Management including treatment
Patients with CNC or with a genetic predisposition to
CNC (i.e. PRKAR1A germline mutation carriers) should
have regular screening for manifestations of the disease.
At present, it is not possible to produce evidenced-based
recommendations for the screening schedule. However,
there is general agreement on the following recommenda-
tions. Clinical work-up for all the manifestations of CNC
should be performed at least once a year in all patients
and should start in infancy. Cardiac myxomas are one of
the main features of CNC and should be diagnosed early
through screening performed at least once a year by car-
diac ultrasound. In patients with a history of cardiac
myxoma, screening should be performed every 6 months.
Screening for cardiac myxoma by ultrasound should start
during the first 6 months. In contrast, screening for the
other manifestations (only by clinical examination)
should be performed in patients under 5 years-old. For
children, pubertal staging and growth rate should be
monitored. Biological and hormonal work-up should
include: measurement of the levels of blood glucose, uri-
nary cortisol, plasma and/or salivary circadian variations
of cortisol, plasma ACTH, GH, PRL, Insulin-Like-Growth-
Factor I, and ionograms. Imaging investigations should
include: adrenal CT-scan (in cases with biological evi-
dence of Cushing's syndrome), thyroid ultrasound (in
cases with abnormal palpation), testicular or ovarian
ultrasound, pituitary MRI, and spine MRI when the clini-
cal signs suggest schwannoma. These imaging investiga-
tions do not always need to be performed each year; the
necessity will be determined according to the history and
previous imaging results, as well as the present clinical
data and results of biological investigations.
A cardiac myxoma requires surgical removal. Treatment of
the other manifestations should be discussed and may
include follow-up, surgery, or medical treatment depend-
ing on the location of the tumor, its size, the existence of
clinical signs of tumor mass or hormonal excess, and the
suspicion of malignancy. Malignancy in CNC is mostly
observed in thyroid nodes (fine-needle investigation is
helpful for diagnosis) and melanotic schwannoma (esti-
mated rate of malignancy: 10 %). Bilateral adrenalectomy
is the most common treatment for Cushing's syndrome
due to PPNAD. Some rare cases have been treated by O,
p'-dichlorodiphenyldichloroethane (DDD), ketoconazol,
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or unilateral adrenalectomy. In the few patients in whom
overt Cushing's syndrome did not recur after unilateral
adrenalectomy, alterations in the rhythm of cortisol secre-
tion can be observed on long term follow-up, demonstrat-
ing that despite apparent cure the disease is indeed
bilateral [17].
Genetic counseling
Genetic analysis should be proposed to all CNC index
cases. When a PRKAR1A mutation is identified, a genetic
analysis should be proposed to first degree relatives. This
is best performed in a multidisciplinary genetic center, in
keeping with the regulations specific to each country. Psy-
chological assessment and management of the patients
might be important when performing genetic screening in
asymptomatic patients. The identification of mutation
carriers should lead to the same follow-up and manage-
ment as that described for CNC patients. Therefore, it is
suggested that genetic screening of first degree relatives is
performed at the same time as the first cardiac ultrasound.
When performing genetic screening in an asymptomatic
child, the parent should be given information about the
fact that a positive screening with identification of a
PRKAR1A mutation should lead to regular screening and
follow-up for CNC manifestations. At present, no recom-
mendation has been made for prenatal diagnosis and this
should be discussed by a multidisciplinary team in keep-
ing with the regulation specific to each country. There are
no reports of prenatal diagnosis of CNC in Europe.
Unresolved questions
No PRKAR1A gene mutations were found in some fami-
lies and the 17q22-24 locus was excluded. The other
gene(s) responsible for CNC remain to be identified. In
CNC kindred without the PRKAR1A mutation, a large
gene deletion or alteration (not detected by the com-
monly used direct sequencing or DHPLC methods) may
be responsible for the condition.
A mutation of the perinatal myosin heavy chain gene has
been reported in patients with trismus-pseudocamptodac-
tyly syndrome. In some of the cases, manifestations of this
syndrome overlap with those observed in CNC [18].
However, the phenotype differs from CNC and at present
it does not seem that this gene is involved in kindreds
with the classic diagnostic criteria of CNC [19].
The subgroup of very young infants with isolated PPNAD,
no other personal or familial history of CNC and no
PRKAR1A mutation may have a separate disease.
Some rare manifestations of the disease (such as osteo-
chondromyxoma) have not yet been extensively
described.
The mechanism of PRKAR1A mutation-induced tumori-
genesis is currently under extensive investigation and is an
important field of research.
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